Analytical Tool - Breast Cancer R&D: A Comprehensive Guide 2005 - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/306279

Analytical Tool - Breast Cancer R&D: A Comprehensive Guide 2005

Description:

This is the second analytical tool to analyze the future competitive situation of breast cancer therapeutics. More updated and extensive, this version pays considerable attention both to the hormone-based therapeutics as well as the new drugs under development. As new data is emerging, for the recent approved aromatase inhibitor, the therapeutic options are about to change. Replacing Tamoxifen, a selective estrogen receptor modulator that has been used for more than 20 years to treat patients with advanced breast cancer. Important aspects, that in turn changes the situation for all investigational drugs, which have to climb over this new barrier to gain regulatory approval. A proof that breast cancer market produces lucrative returns is the near to 50% increase of sales between the year 2003 and 2004 for most of the aromatase inhibitors. Overall combined sales for the top three breast cancer hormone therapies on the market reaching more than $1.8 billion.

"Analytical Tool: Breast Cancer R&D: A Comprehensive Guide" is the ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development. Those who are victorious in the field plan effectively and change decisively. It provides a complete and systematic description and analysis of the past, present and future efforts in cancer R&D from both industry as well as academic. We have identified structured and defined information necessary to analyze the most candidates currently under development. Our included CD-ROM database contains thousands of records on the issue of R&D and collaborations derived from a multitude of sources, e.g. news releases, company sources, conferences, scientific publications, patents and published interviews etc.

This highly updated database reflects the most recent advances in the field. Enabling you to perform your own specific analysis, go back to the source data for in-depth information, and to offer you an opportunity to easily produce tables and graphs of the information suited for your own specific purposes.

Reasons to purchase this Analytical Tool:
- This is the only product that provides you with a complete structure of the areas involved in analyzing breast therapeutics.
- It identifies and structures most B2B collaborations and industry-academic alliances
- It covers close to all areas of cancer therapeutic strategies You will be able to study areas in conjunction to cancer structured by therapy type, drug effects, mechanisms/targets and combinatory therapies
- It enables you to track cutting edge competitive companies, therapies and technologies in the future market
- You will save time and money by rapid identification and analysis of competitors and business opportunities.
- You will be able to evaluate progress in both established as well as novel treatment strategies competing within the field of cancer drug development in big pharma.

This Analytical Tool includes three parts:
Breast Cancer: The Latest R&D Trends
Basic Platform Report: Breast Cancer
Business Development and R&D Database: Breast Cancer

Example of candidates included:
The complete number of candidate drugs in clinical research for breast cancer, are more than 150, and some of them below are listed below:

Abraxane, Alimta, Arimidex, Aromasin, Avastin, BMS-217380-01, BMS-247550, CAELYX, CCI-779, Faslodex, Femara, Fenretinide, Gleevec, GTI-2040, Herceptin, Iressa, ISIS-2503, Lapatinib, Nolvadex, Sarasar, SDX-105, Tarceva, Theratope Velcade, Zarnestra, Zoladex ZD0473 and many other that are in an earlier stage of development.

Companies Mentioned

American Bioscience AnorMED AstraZeneca Biomira Inc Bristol-Myers Squibb Eli Lilly and Company Genentech GlaxoSmithKline ISIS Pharmaceuticals Johnson and Johnson Lorus Therapeutics McNeil Pharmaceuticals Merck KgaA Millennium Pharmaceuticals NeoRx Novartis OSI Pharmaceuticals Pfizer Roche Salmedix, Schering-Plough Wyeth

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/306279

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 06/09/2008 20:08:07

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com

Order information

Please verify that the product information is correct and select the format you require.


Product Name:
Analytical Tool - Breast Cancer R&D: A Comprehensive Guide 2005
Web Address:
http://www.researchandmarkets.com/reports/306279
Office Code:
OCHHHKKQOSQ

Report formats

Please enter the quantity of the report format you require.

	Format	Quantity	Price
	CD ROM		€5,850.00 + EUR€ 50.00 Shipping/Handling *

* Shipping/Handling is only charged once per order.

Contact information

Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Page 2 of 2
Printed 06/09/2008 20:08:07

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder Name:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World